Literature DB >> 9620510

The effects of pentobarbital on blood-brain barrier disruption caused by intracarotid injection of hyperosmolar mannitol in rats.

O Z Chi1, T W Chun, X Liu, H R Weiss.   

Abstract

UNLABELLED: This study was performed to evaluate both the effects of pentobarbital on disruption of the blood-brain barrier (BBB) by hyperosmolar mannitol and the relationship between its effect on blood pressure and the integrity of the BBB. Under isoflurane anesthesia, rats in the control group were infused with 25% mannitol into the internal carotid artery before measuring the transfer coefficient (Ki) of 14C alpha-aminoisobutyric acid. Ten minutes before the administration of mannitol, rats received an infusion of pentobarbital: 20 mg/kg in the small-dose group and 50 mg/kg in the large-dose group. In another group of animals (hydralazine group), hydralazine was administered to maintain the mean arterial blood pressure (MAP) at 65 mm Hg during the experimental period. The MAP of the control group (113 +/- 14 mm Hg) was significantly higher (P < 0.002) than that of the small-dose pentobarbital group (78 +/- 13 mm Hg) or the large-dose pentobarbital group (68 +/- 14 mm Hg). In the control group, the Ki of the cortex ipsilateral to the mannitol injection was increased to 4.5 times that of the contralateral cortex (14.5 +/- 7.7 vs 3.2 +/- 0.6 microL x g(-1) x min(-1); P < 0.002). The Ki of the ipsilateral cortex of the small-dose pentobarbital group was 9.7 +/- 5.6 microL x g(-1) x min(-1). The Ki of the ipsilateral cortex of the large-dose pentobarbital group was 5.5 +/- 2.9 microL x g(-1) x min(-1), and lower (-9.0 microL x g(-1) x min(-1)) than that of the control animals (P < 0.05). There was no significant difference in the Ki of the contralateral cortex among any of the three groups of animals. At the same MAP, the Ki of the ipsilateral cortex of the large-dose pentobarbital group was lower (-4.3 microL x g(-1) x min(-1)) than that of the hydralazine group (9.8 +/- 4.6 microL x g(-1) x min(-1)) (P < 0.05). Pentobarbital attenuated the BBB disruption induced by hyperosmolar mannitol. This may be attributed, at least in part, to the blood pressure effect of pentobarbital. IMPLICATIONS: When the blood-brain barrier (BBB) was disrupted by a hyperosmolar solution, pentobarbital attenuated the degree of leakage of the BBB. Systemic hypotension caused by pentobarbital played a significant role in decreasing the leakage. Our study suggests that when the BBB is disrupted, pentobarbital may be effective in protecting the BBB. Furthermore, systemic blood pressure plays an important role in determining the degree of disruption.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9620510     DOI: 10.1097/00000539-199806000-00018

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  5 in total

Review 1.  Targeting the brain: rationalizing the novel methods of drug delivery to the central nervous system.

Authors:  Shailendra Joshi; Eugene Ornstein; Jeffrey N Bruce
Journal:  Neurocrit Care       Date:  2007       Impact factor: 3.210

2.  Inconsistent blood brain barrier disruption by intraarterial mannitol in rabbits: implications for chemotherapy.

Authors:  Shailendra Joshi; Aysegul Ergin; Mei Wang; Roberto Reif; Jane Zhang; Jeffrey N Bruce; Irving J Bigio
Journal:  J Neurooncol       Date:  2010-12-12       Impact factor: 4.130

Review 3.  Intracarotid delivery of drugs: the potential and the pitfalls.

Authors:  Shailendra Joshi; Phillip M Meyers; Eugene Ornstein
Journal:  Anesthesiology       Date:  2008-09       Impact factor: 7.892

4.  Autoantibodies against NMDAR subunit NR1 disappear from blood upon anesthesia.

Authors:  Johannes Teller; Carolin Jung; Justus B H Wilke; Svea-Dorothée Schimmelpfennig; Martin Hindermann; Lukas Hinken; Maria M Gabriel; Christine Fegbeutel; Andreas Schäfer; Hans Laser; Ralf Lichtinghagen; Hans Worthmann; Karin Weissenborn; Hannelore Ehrenreich
Journal:  Brain Behav Immun Health       Date:  2022-08-04

5.  Localized anesthesia of a specific brain region using ultrasound-responsive barbiturate nanodroplets.

Authors:  Harriet Lea-Banks; Meaghan A O'Reilly; Clement Hamani; Kullervo Hynynen
Journal:  Theranostics       Date:  2020-02-03       Impact factor: 11.556

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.